On a year-on-year (YoY) basis, the company’s net profit rose 26.74%, while revenue increased 13.78%, indicating continued growth over the previous year despite the sequential decline.
Profit before tax for the quarter stood at Rs 733 crore, down 15.16% QoQ but up 21.35% YoY.
The company reported a forex gain of Rs 39 crore during the quarter, compared to a forex loss of Rs 1 crore in the corresponding quarter of the previous financial year.
On a standalone basis, the company’s net profit surged 29.53% to Rs 557 crore on a 14.25% rise in revenue to Rs 2,357 crore in Q1 FY26 over Q1 FY25.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."